Cannabis for appetite loss has been studied mainly in people with cancer and in people with HIV/AIDS, and the results are few and mixed. The 2022 systematic review of appetite-related symptoms in people with cancer found that efficacy was shown in one trial only. Symptom relief is not tumor response, cure or survival benefit, so a better appetite should not be read as a sign that a cancer is responding to treatment.
Which populations and outcomes were studied?
The 2022 review included five randomized trials of people with cancer. They compared dronabinol, nabilone or a cannabis extract against placebo in four trials and against megestrol acetate in one. Measures and trial endpoints varied, and the review concluded that evidence from randomized trials that medicinal cannabis increases appetite in people with cancer is limited.
Two other studies measured appetite hormones rather than appetite itself. A 2012 pilot study in HIV-infected adult men gave smoked medicinal cannabis and placebo in a crossover design and found higher ghrelin and leptin and lower PYY with cannabis. A 2020 randomized, placebo-controlled study in 20 cannabis users compared oral, smoked and vaporized cannabis with placebo and measured insulin, GLP-1, ghrelin and leptin.
| Population | Formulation | Comparator | Outcome | Duration | Harms | Certainty |
|---|---|---|---|---|---|---|
| People with cancer (five randomized trials, 2022 review) | Dronabinol, nabilone, cannabis extract | Placebo (four trials) or megestrol acetate (one trial) | Appetite-related symptoms; benefit shown in one trial (taste of food, premeal appetite, protein share of calories) | Varied across trials | Generally well tolerated; toxicity measurement was limited | Limited; the review concludes evidence is limited |
| HIV-infected adult men (2012 pilot) | Smoked medicinal cannabis (THC) | Placebo, crossover design | Ghrelin and leptin higher, PYY lower; insulin not significantly changed | One crossover comparison of cannabis and placebo | Harms not reported as an outcome; the hormone changes are measurements, not confirmed adverse effects. | Pilot study; small crossover design |
| Adults who use cannabis (2020 study) | Oral, smoked and vaporized THC cannabis | Placebo, randomized crossover | Insulin response blunted; GLP-1 lower; total ghrelin higher with oral cannabis than with smoked or vaporized | Four sessions per participant | Harms not reported as an outcome; the hormone changes are measurements, not confirmed adverse effects. | Small laboratory study of 20 people |
What did the studies measure, and what does that mean for you?
The one cancer trial that showed a benefit measured taste of food, premeal appetite and the proportion of calories consumed as protein. The hormone studies measured blood levels of ghrelin, leptin, insulin, GLP-1 and PYY. A change in a hormone is a biological signal, not proof that a person eats more, gains weight or feels better. A 2011 review of cannabis and appetite regulation discusses how non-THC cannabinoids may affect feeding patterns, but it is a review of mechanisms rather than a trial in people with appetite loss. For the basics of the system involved, see The Endocannabinoid System and CBD: A Plain-English Guide.
Is symptom relief the same as treating cancer?
No. Appetite is a symptom. The studies above measured appetite and hormone markers, not whether a tumor shrinks, whether a cancer is cured or whether people live longer. The 2022 review describes anorexia as a prevalent and distressing symptom in people with cancer, with limited effective interventions. For cancer, supportive care for symptoms is kept separate from disease-directed treatment.
What regulators say about cannabis for appetite
Check the FDA’s cannabis regulation page for current regulatory status before you decide. For the synthetic THC-based products dronabinol (Marinol, Syndros) and nabilone (Cesamet), confirm on each product’s label whether it is prescribed for your condition and how it must be obtained, or ask your prescriber.
What underlying causes need clinical assessment?
The studies here focus on people with cancer and people with HIV/AIDS, where appetite loss is a known problem. A sudden or lasting loss of appetite can have many causes, and finding the cause is a job for a clinician before any treatment is weighed. The 2012 pilot study found higher ghrelin and leptin and lower PYY with cannabis compared with placebo, and the 2020 study found cannabis changed several appetite-related hormones. Tell your clinician about any cannabis use, because it can change how you read appetite changes.
Does cannabis make you hungry?
The 2012 study found that THC raised ghrelin and leptin and lowered PYY compared with placebo, which fits the idea that cannabis affects appetite signals. These studies measured hormones and appetite symptoms, not weight gain over time in people with appetite loss. Consumer sites often rank strains for appetite; those rankings are not trials of appetite, and the studies above are what the research has measured. If you are weighing whether cannabis suits a symptom you have, read When Cannabis Is Not Helping: Symptoms, Safety and Next Steps.
What to ask your oncology team about supportive care and interactions
Your next step is to ask your oncology team about supportive care for appetite. Bring a list of every medicine and supplement you take, and have your oncology team or pharmacist review that list for interactions with any cannabis product you are considering. The 2022 review found the cannabis medicines generally well tolerated but said toxicities were not comprehensively measured. For how trials count side effects, see Trial Adverse Events: Denominators, Severity, and Follow-Up.
Before your appointment, write down:
- What is causing the appetite change, and what has been ruled out.
- Whether any of the trials above would apply to your treatment.
- How any cannabinoid option would interact with your current medicines.
- Which side effects you should report, and to whom.
By TakeHempGummies.com Consumer Research Desk
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.